Iovance Biotherapeutics to Present at Two Investor Conferences in June

SAN CARLOS, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in June:

• Jefferies 2018 Global Healthcare Conference in New York, NY on Thursday, June 7, 2018 at 9:00 a.m. ET
• JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 20, 2018 at 1:00 p.m. ET  

A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.

About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.

Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] Media Contact: Evan Smith FTI Consulting 212-850-5622 [email protected] 

Source: Iovance Biotherapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Real Life-Size Human Anatomy in Your Hands with Anatomage Replica
• DSC Foundation Gala Draws Global Support, Unites Conservationists, and Honors Steve Hornady
• Liberty Military Housing Announces New Chief Financial Officer